Rate of Cough During Treatment With Angiotensin‐Converting Enzyme Inhibitors: A Meta‐Analysis of Randomized Placebo‐Controlled Trials

@article{Vukadinovi2019RateOC,
  title={Rate of Cough During Treatment With Angiotensin‐Converting Enzyme Inhibitors: A Meta‐Analysis of Randomized Placebo‐Controlled Trials},
  author={Davor Vukadinovi{\'c} and Aleksandra Nikolovska Vukadinovi{\'c} and Daniel Lavall and Ulrich Laufs and Stefan Wagenpfeil and Michael B{\"o}hm},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2019},
  volume={105}
}
Use of protective angiotensin‐converting enzyme inhibitors (ACE‐I) in patients with cardiovascular disease (CVD) is sometimes limited by incident coughing. In clinical trials, cough occurred also on placebo. We performed a meta‐analysis including randomized, placebo‐controlled trials reporting cough on ACE‐I in patients with CVD. We evaluated the attributable fraction of cough on ACE‐I accounting rate on placebo: placebo‐adjusted ACE‐I (%) = (ACE‐I (%) – Placebo (%)) / ACE‐I (%). In total, 65… 
Response to “Discontinuation of Angiotensin Converting Enzyme Inhibitors Due to Dry Cough: Incidence and Clinical Determinants”
TLDR
Older age, female gender, and concomitant use of lipidlowering agents are determinants associated with cough which led to discontinuation of ACEI, and association of female gender with higher rates of cough in patients on perindopril confirmed earlier findings from epidemiological studies.
Clinical Factors and Rate of Cough During Angiotensin‐Converting Enzyme Inhibitor Treatment
TLDR
The incidence of cough differed between underlying conditions, with highest placeboadjusted rates of cough in arterial hypertension and lowest place boad justed rates in heart failure, potentially because of the prevalence of smoking, which likely might contribute in the latter.
Discontinuation of Angiotensin Converting Enzyme Inhibitors due to Dry Cough: Incidence and Clinical Determinants
  • J. Brugts
  • Medicine
    Clinical pharmacology and therapeutics
  • 2019
TLDR
This study showed an incidence of cough leading to discontinuation of ACEinhibitors of 3.9%, which is overall lower as compared to literature, and underscribe that comprehensive evaluation of cough ruling out other causes of cough is essential.
Response to “Clinical Factors and Rate of Cough During Angiotensin‐Converting Enzyme Inhibitor Treatment”
TLDR
Evidence is not sufficient to support the statement that smoking reduces the ACEI related cough, and the present study points to the importance of genetic polymorphism as a predictor of this adverse effect, which could explain why some individuals develop cough on ACEIs and others do not.
Angiotensin-Converting Enzyme Inhibitors, Asthma, and Cough: Relighting the Torch.
  • W. Song, A. Niimi
  • Medicine
    The journal of allergy and clinical immunology. In practice
  • 2021
Angiotensin-Converting Enzyme Inhibitors Induce Cough.
  • İ. Yılmaz
  • Medicine, Biology
    Turkish thoracic journal
  • 2019
TLDR
In this review, the mechanisms that are suggested in ACE-I-induced cough pathophysiology will be discussed in detail in light of the current literature.
Drug-Induced Cough.
TLDR
Recent knowledge on drug-induced coughs in patients with chronic cough is presented and the focus is placed on ACEIs, for which there are a multitude of studies documenting their associations with cough.
The presence of underlying asthma should be investigated in patients diagnosed with ACE inhibitor induced cough
Why do only some of patients who are prescribed angiotensin converting enzyme inhibitors (ACE‐I) develop cough? The pathogenesis of ACE‐I‐induced cough remains controversial and requires further
Efficacy of perindopril/amlodipine and valsartan/amlodipine combinations in patients with a combination of arterial hypertension and chronic obstructive pulmonary disease
TLDR
Any of the studied combinations, which demonstrated comparable efficacy and tolerability in the study, can be recommended as the first step of antihypertensive therapy in patients with arterial hypertension in combination with chronic obstructive pulmonary disease.
...
1
2
...

References

SHOWING 1-10 OF 50 REFERENCES
Angiotensin‐Converting Enzyme Inhibitors and Cough: A Prospective Evaluation in Hypertension and in Congestive Heart Failure
TLDR
Angiotensin‐converting enzyme inhibitors (ACE‐I) have become the mainstem of antihypertensive therapy and first‐choice agents for vasodilatation in congestive heart failure (CHF) and should be continued in most patients despite the cough, which will subsequently regress in intensity or disappear.
Effects of modulators of the renin—angiotensin—aldosterone system on cough
TLDR
The incidence of cough related to the type 1 Ang II receptor antagonist losartan is significantly lower than that observed with lisinopril, and similar to that seen with hydrochlorothiazide in patients with a rechallenged ACE inhibitor cough.
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients
TLDR
In patients with hypertension, treatment with an ACE inhibitor results in a significant further reduction in all-cause mortality, and the widespread use of ACE inhibitors may result in an important gain in lives saved.
Zofenopril and incidence of cough: a review of published and unpublished data
TLDR
Evidence from a limited number of studies indicates a relatively low incidence of zofenopril-induced cough.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
TLDR
Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice
TLDR
ACE inhibitors, ARBs, BBs and MRAs are under-prescribed in eligible HFREF patients and should be made to improve approaches to closing the treatment gap at both systems of care and individual levels.
...
1
2
3
4
5
...